Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive aspects such as the well-powered trial, competitive positioning, and market potential, there are concerns about the lack of specific data and potential side effects like weight gain. The Q&A indicates cautious optimism but also highlights uncertainties, particularly regarding trial outcomes and regulatory perspectives. The absence of new partnerships or strong financial guidance further tempers expectations, leading to a neutral sentiment.
Key Financial Performance
Cash, Cash Equivalents, and Short-Term Deposits EUR 230.9 million as of December 31, 2025, built by two significant financing events in 2025: the execution of the second tranche of 2024 structured financing in May (EUR 108 million in net proceeds) and a U.S. registered public offering in November (EUR 139.4 million in net proceeds).
R&D Expenses EUR 87 million for the full year 2025, primarily reflecting pipeline prioritization and the completion of NATiV3 enrollment in April 2025.
Marketing and Business Development Expenses EUR 5 million for the full year 2025, primarily due to planned pre-commercial investment expenses for the potential launch of lanifibranor.
G&A Expenses EUR 47.9 million for the full year 2025, including EUR 20.3 million of noncash share-based compensation tied to governance and organizational transition.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lanifibranor: Lanifibranor is the primary focus of Inventiva, aimed at treating MASH. It is a small molecule designed to induce anti-fibrotic, anti-inflammatory, and beneficial vascular and metabolic changes. It has shown statistically significant improvement in fibrosis and MASH resolution in Phase IIb trials. The pivotal Phase III NATiV3 trial is fully enrolled with over 1,000 patients, and top-line results are expected in Q4 2026.
MASH Market Opportunity: There are an estimated 18 million people in the U.S. living with MASH, but only 10% are diagnosed. Diagnosis rates have grown by 25% compared to 2024. Lanifibranor is positioned as a potential best-in-disease oral therapy with significant commercial impact if approved.
Pipeline Prioritization: Inventiva has strategically focused all resources on lanifibranor and MASH. The company sold global rights to odiparcil for up to $90 million in milestone payments and royalties, freeing resources for lanifibranor development.
Financial Position: As of December 31, 2025, Inventiva held EUR 230.9 million in cash and equivalents, with a cash runway extending to Q1 2027 or Q3 2027 with additional warrant exercises. R&D expenses were EUR 87 million, reflecting pipeline prioritization.
Leadership Strengthening: Inventiva has strengthened its leadership team with new appointments, including a Chief Medical Officer, EVP of Quality and Regulatory Affairs, and Chief Commercial Strategy Officer, to align with its strategic focus on lanifibranor and MASH.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Trial Risks: The success of the NATiV3 Phase III clinical trial is critical for the approval of lanifibranor. Any delays or negative outcomes in the trial could significantly impact the company's strategic objectives and financial performance.
Market Adoption Challenges: Despite the growing awareness and diagnosis rates of MASH, only 10% of the estimated 18 million patients in the U.S. have been diagnosed, and only 40% of those with clinically actionable disease are under care. This indicates potential challenges in market penetration and adoption of lanifibranor.
Financial Sustainability: While the company is funded beyond the NATiV3 readout, its cash runway is limited to Q1 2027 or Q3 2027 with additional warrant exercises. This creates financial pressure to achieve regulatory approval and commercial success within this timeframe.
Competitive and Market Risks: The company faces competition in the MASH treatment space, and the success of lanifibranor depends on its ability to demonstrate superior efficacy and safety compared to existing and emerging therapies.
Operational Risks: The company has undergone significant organizational changes, including leadership transitions and strategic focus shifts. These changes may pose risks to operational stability and execution of strategic plans.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expected timing of top-line readout for NATiV3 trial: The top-line readout for the NATiV3 trial is anticipated in Q4 2026.
Potential regulatory and commercial milestone payments from odiparcil sale: Inventiva may receive up to $90 million in potential regulatory and commercial milestone payments, as well as high single-digit royalties on future net sales if approved.
Market opportunity for lanifibranor in MASH: There are an estimated 18 million people in the U.S. living with MASH, with only 10% diagnosed. Diagnosis rates have grown by 25% compared to 2024 estimates. Lanifibranor could potentially become a best-in-disease oral therapy if the NATiV3 trial replicates the 18% fibrosis improvement seen in Phase II.
Anticipated cash runway: Inventiva estimates its cash runway extends to the middle of Q1 2027, and to the middle of Q3 2027 if tranche 3 warrants are fully exercised, potentially generating an additional EUR 116 million.
Regulatory and commercial readiness for lanifibranor: Preparations for regulatory submissions (NDA and MAA) and commercialization are progressing in parallel, with a focus on a potential launch of lanifibranor if approved.
NATiV3 trial design and patient population: The NATiV3 trial is designed to confirm and extend Phase IIb findings in a larger, diverse global population over 72 weeks. It includes over 1,000 patients in the main cohort and an additional 410 patients in an exploratory cohort.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you update us on how the performance of the trial has been in terms of dropouts?
A:The early termination rate for the trial needed to be below 30%, as per the structured financing covenants. The trial is well within that range, and the company is reaffirming that the trial is well-powered to detect the primary endpoint.
Q:Can you help us understand how you're thinking about the performance of the 800 versus the 1,200-milligram dose in terms of both weight gain and fibrosis?
A:The 800-milligram dose may catch up to the 1,200-milligram dose over time due to the biology of PPARs. Weight gain, a PPAR gamma-mediated fluid retention event, is likely dose-dependent. Both doses are expected to show strong efficacy, with the 800-milligram dose potentially having a better tolerability profile.
Q:What are you seeing in terms of the overall market interest and the opportunity to compete with Madrigal?
A:The company believes an 18% effect on fibrosis would make their drug highly competitive. They see significant market growth and unmet needs, particularly in the F3 diabetic patient population, where their drug could have a strong entry point.
Q:What are some of the quality control protocols in place to analyze biopsy samples for the NATiV3 trial?
A:Quality control involves ensuring proper biopsy procedures, capturing biopsies according to standard practices, and maintaining quality during slide preparation. The team is experienced in MASH clinical trials and is confident in their processes.
Q:Have there been any recent safety monitoring committee meetings, and are there any updates on the safety profile?
A:Periodic safety monitoring committee meetings occur every six months. No specific details were disclosed, but the company stated that no significant safety concerns have been raised.
Q:What is the effect size for the primary combined endpoint in the NATiV3 trial, and what are the expectations for placebo response?
A:The trial is powered to over 90% for the primary endpoint, with a higher placebo response and smaller treatment effect than in Phase II. The placebo response for the composite endpoint is expected to remain low, reflecting the underlying biology.
Q:How is the company viewing the F3 diabetic population and its market potential?
A:The F3 diabetic population is a large segment, with 55-65% of patients being diabetic. Diagnosis rates are increasing, and the company sees significant growth potential in this segment.
Q:How many F4 patients are in the exploratory cohort, and what is the company hoping to learn from this cohort?
A:The exploratory cohort includes F4 patients who are compensated and have varying severity. The company aims to assess safety, pharmacology, and progression to later-stage disease, which will inform the design of future outcome-driven trials.
Q:What are the expectations for weight gain in the trial, and how will regulators view this issue?
A:Weight gain is expected to plateau and may be mitigated by concomitant medications like SGLT2 inhibitors. Regulators are familiar with fluid retention as a known PPAR gamma effect, and no significant cardiac imbalances have been observed in the program.
Q:What is the overlap between MASH and type 2 diabetes, and how does the company plan to address this segment?
A:There are approximately 18 million undiagnosed MASH patients in the U.S., with over half having diabetes. The company plans to focus on already diagnosed patients initially and may later work to increase diagnosis rates.
Q:What steps are being taken to prepare for regulatory approval and commercialization?
A:The regulatory team is fully staffed, and the company is focusing on strategic commercial execution, including market access and medical affairs. Commercial staffing will increase only after positive data is obtained.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the actual effect size for the primary endpoint in the NATiV3 trial, stating only that it is smaller than in Phase II. They also did not disclose the exact number of F4 patients in the exploratory cohort or when data from this cohort will be available. Additionally, they did not provide details on the potential impact of background GLP-1 use on the trial's outcomes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Campagna
Chief Medical
EUR proceeds
Financial
Head
III trial
Lanifibranor
MASH fibrosis
MASH resolution
Medical Officer
Phase III
Phase IIb
President RD
Slide
afternoon Inventiva
care
decision
disease
fibrosis improvement
floor
focus
improvement MASH
lanifibranor treatment
launch
liver failure
metabolic
middle
number
odiparcil
progression liver
resource lanifibranor
result Phase
risk progression
therapy
yesterday evening
IVA Transcript
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Unknown3-31
The earnings call presents a mixed picture. While there are positive aspects such as the well-powered trial, competitive positioning, and market potential, there are concerns about the lack of specific data and potential side effects like weight gain. The Q&A indicates cautious optimism but also highlights uncertainties, particularly regarding trial outcomes and regulatory perspectives. The absence of new partnerships or strong financial guidance further tempers expectations, leading to a neutral sentiment.
Inventiva S.A. (IVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Inventiva S.A. (IVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call highlights several concerning factors: a significant decline in revenue and net financial loss, competitive pressures in MASH treatment, and potential supply chain challenges. While cash position improved, the lack of shareholder return programs and increased net loss are negative. The Q&A reveals operational uncertainties and unclear management responses, further dampening sentiment. Despite some positive cash flow from financing, the overall financial health and competitive landscape raise concerns, leading to a negative outlook.
IVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
